Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

Contemporary Forums

The Synagis Debate: RSV Risk, Revised Recommendations, and Rising Cost

Access Activity

Overview / Abstract:

Learning Objectives:
Discuss the prevalence of RSV and risk of hospitalization from severe disease across all neonatal and infant populations.
Analyze data regarding palivizumab efficacy and cost effectiveness.
Review revised 2014 palivizumab recommendations and discuss validity of changes.


May 26, 2018


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME





Credits / Hours

1.25 hours, Rx=.75



Presenters / Authors / Faculty

Heather Monk-Bodenstab PharmD
Program Consultant
Clinical Specialist, Newborn/Infant Intensive Care and Bone Health
Department of Pharmacy Services
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Activity Specialities / Related Topics

Pulmonary Medicine / COPD, Pharmacology, Perinatology, Pediatrics

Keywords / Search Terms

Contemporary Forums Online NICU, pharmacology, RSV, infants, preterm, neonatal, palivizumab, lung disease,

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.